Cargando…

Investigating and modeling positron emission tomography factors associated with large cell transformation from low‐grade lymphomas

Low‐grade lymphomas have a 1%–3% annual risk of transformation to a high‐grade histology, and prognostic factors remain undefined. We set to investigate the role of positron emission tomography (PET) metrics in identification of transformation in a retrospective case‐control series of patients match...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obeid, Jean‐Pierre, Hiniker, Susan M., Schroers‐Martin, Joseph, Guo, H. Henry, No, Hyunsoo Joshua, Moding, Everett J., Advani, Ranjana H., Alizadeh, Ash A., Hoppe, Richard T., Binkley, Michael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Haematologic Malignancy ‐ Lymphoid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928791/ https://www.ncbi.nlm.nih.gov/pubmed/36819184 http://dx.doi.org/10.1002/jha2.615

Ejemplares similares

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020)

Primary central nervous system lymphoma: Inter‐compartmental progression
por: Raval, Vishal, et al.
Publicado: (2022)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis
por: García‐Abellás, Patricia, et al.
Publicado: (2022)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

Targetable alterations in primary extranodal diffuse large B‐cell lymphoma
por: Weissinger, Stephanie E., et al.
Publicado: (2022)

Characteristics and prognosis of distant metastasis after primary treatment for early‐stage extranodal nasal‐type natural killer/T‐cell lymphoma from the China Lymphoma Collaborative Group database
por: Zheng, Xuan, et al.
Publicado: (2022)

Marginal zone lymphoma expression of histidine‐rich glycoprotein correlates with improved survival
por: Persson Skare, Tor, et al.
Publicado: (2020)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma
por: Yagi, Yu, et al.
Publicado: (2023)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

B‐cell receptors of EBV‐negative Burkitt lymphoma bind modified isoforms of autoantigens
por: Bock, Theresa, et al.
Publicado: (2022)

The added prognostic values of baseline PET dissemination parameter in patients with angioimmunoblastic T‐cell lymphoma
por: Gong, Huanyu, et al.
Publicado: (2022)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Clinical features and outcomes of duodenal‐type follicular lymphoma: A single‐center retrospective study
por: Kamijo, Kimimori, et al.
Publicado: (2022)

First‐line antibiotic treatment in patients with localized extragastric mucosa‐associated lymphoid tissue lymphoma
por: Yao, Ming, et al.
Publicado: (2022)

HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication
por: Wang, Chaoyu, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis
por: Le Bris, Yannick, et al.
Publicado: (2022)

Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly
por: Junlén, Henna‐Riikka, et al.
Publicado: (2023)

Therapeutic efficacy of the resorcylic acid lactone LL‐Z1640‐2 for adult T‐cell leukaemia/lymphoma
por: Oura, Masahiro, et al.
Publicado: (2023)

Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2022)

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
por: Spriano, Filippo, et al.
Publicado: (2022)

A nomogram prognostic model for diffuse large B‐cell lymphoma based on SUVmax and GNRI in elderly patients
por: Li, Maoqin, et al.
Publicado: (2023)

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
por: Gunawardana, Jay, et al.
Publicado: (2020)

A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus
por: Dittus, Christopher, et al.
Publicado: (2022)

Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
por: Wahlin, Björn Engelbrekt, et al.
Publicado: (2021)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts MYC rearrangements in large B‐cell lymphoma
por: García, Rolando, et al.
Publicado: (2022)

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
por: Bishton, Mark J., et al.
Publicado: (2022)

First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2022)

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
por: Karmali, Reem, et al.
Publicado: (2022)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)
por: Narkhede, Mayur, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tflo9in3e70mpjhu0bl2sk2pa0